JP2006219454A5 - - Google Patents

Download PDF

Info

Publication number
JP2006219454A5
JP2006219454A5 JP2005036235A JP2005036235A JP2006219454A5 JP 2006219454 A5 JP2006219454 A5 JP 2006219454A5 JP 2005036235 A JP2005036235 A JP 2005036235A JP 2005036235 A JP2005036235 A JP 2005036235A JP 2006219454 A5 JP2006219454 A5 JP 2006219454A5
Authority
JP
Japan
Prior art keywords
agent according
therapeutic
prophylactic agent
dgla
skin disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005036235A
Other languages
Japanese (ja)
Other versions
JP2006219454A (en
JP5546087B2 (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP2005036235A external-priority patent/JP5546087B2/en
Priority to JP2005036235A priority Critical patent/JP5546087B2/en
Priority to PCT/JP2006/302787 priority patent/WO2006085687A1/en
Priority to EP06713928.7A priority patent/EP1852114B1/en
Priority to CA2599112A priority patent/CA2599112C/en
Priority to EP19183855.6A priority patent/EP3581178B1/en
Priority to US11/884,199 priority patent/US9006287B2/en
Priority to CN 200610003112 priority patent/CN101019853B/en
Priority to CN2012100164426A priority patent/CN102600174A/en
Publication of JP2006219454A publication Critical patent/JP2006219454A/en
Publication of JP2006219454A5 publication Critical patent/JP2006219454A5/ja
Publication of JP5546087B2 publication Critical patent/JP5546087B2/en
Application granted granted Critical
Priority to US14/644,231 priority patent/US9943495B2/en
Priority to US15/911,806 priority patent/US10342773B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (12)

ジホモ−γ−リノレン酸（DGLA）を有効成分として含有する、皮膚疾患治療または予防剤。   A skin disease treatment or prevention agent comprising dihomo-γ-linolenic acid (DGLA) as an active ingredient. 前記皮膚疾患がアトピー性皮膚炎である、請求項１に記載の治療または予防剤。   The therapeutic or prophylactic agent according to claim 1, wherein the skin disease is atopic dermatitis. 前記皮膚疾患が紫外線による皮膚障害である、請求項１に記載の治療または予防剤。   The therapeutic or prophylactic agent according to claim 1, wherein the skin disease is a skin disorder caused by ultraviolet rays. DGLAの摂取量が、成人１人１日当り5mg〜600mgである、請求項１〜３のいずれか1項に記載の治療または予防剤。   The therapeutic or prophylactic agent according to any one of claims 1 to 3, wherein the intake of DGLA is 5 mg to 600 mg per adult per day. DGLAの摂取量が、成人１人１日当り5mg〜200mgである、請求項１〜３のいずれか1項に記載の治療または予防剤。   The therapeutic or prophylactic agent according to any one of claims 1 to 3, wherein the intake of DGLA is 5 mg to 200 mg per day per adult. DGLAの摂取量が、成人１人１日当り5mg〜150mgである、請求項１〜３のいずれか1項に記載の治療または予防剤。   The therapeutic or prophylactic agent according to any one of claims 1 to 3, wherein the intake of DGLA is 5 mg to 150 mg per adult per day. 前記DGLAが、グリセライド、リン脂質、糖脂質、アルキルエステル、又は遊離脂肪酸の形態で存在する、請求項１〜６のいずれか1項に記載の治療または予防剤。   The therapeutic or prophylactic agent according to any one of claims 1 to 6, wherein the DGLA is present in the form of glyceride, phospholipid, glycolipid, alkyl ester, or free fatty acid. 前記グリセライドが、トリグリセライド、ジグリセライド、又はモノグリセライドである、請求項７に記載の治療または予防剤。   The therapeutic or prophylactic agent according to claim 7, wherein the glyceride is triglyceride, diglyceride, or monoglyceride. DGLAレベルの低い人の皮膚疾患を治療するための、請求項１〜８に記載の治療または予防剤。   The therapeutic or prophylactic agent according to any one of claims 1 to 8, which is for treating a skin disease of a person having a low DGLA level. 前記DGLAレベルの低い人が、Δ6不飽和酵素及び／又は炭素鎖伸長化酵素が機能不全、不十分、または欠乏している人である、請求項９に記載の治療または予防剤。   10. The therapeutic or prophylactic agent according to claim 9, wherein the person having a low DGLA level is a person whose Δ6 unsaturated enzyme and / or carbon chain elongation enzyme is dysfunctional, insufficient or deficient. 請求項１〜10のいずれかの項に記載の皮膚疾患治療または予防剤を含む、食品組成物または医薬組成物。   A food composition or a pharmaceutical composition comprising the skin disease treatment or prevention agent according to any one of claims 1 to 10. 前記医薬組成物が経口用である請求項11に記載の組成物。   12. The composition according to claim 11, wherein the pharmaceutical composition is for oral use.
JP2005036235A 2005-02-14 2005-02-14 Oral treatment or prevention agent for skin diseases Active JP5546087B2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2005036235A JP5546087B2 (en) 2005-02-14 2005-02-14 Oral treatment or prevention agent for skin diseases
PCT/JP2006/302787 WO2006085687A1 (en) 2005-02-14 2006-02-10 Composition containing dihomo-ϝ-linolenic acid (dgla) as the active ingredient
EP06713928.7A EP1852114B1 (en) 2005-02-14 2006-02-10 Composition containing dihomo-y-linolenic acid (dgla) as active ingredient
CA2599112A CA2599112C (en) 2005-02-14 2006-02-10 Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient
EP19183855.6A EP3581178B1 (en) 2005-02-14 2006-02-10 Composition containing dihomo-(gamma)-linolenic acid (dgla) as active ingredient
US11/884,199 US9006287B2 (en) 2005-02-14 2006-02-10 Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient
CN 200610003112 CN101019853B (en) 2005-02-14 2006-02-14 Composition containing dihomo-gamma-linolenic acid (DGLA) as the active ingredient
CN2012100164426A CN102600174A (en) 2005-02-14 2006-02-14 Composition comprising dihomo-.gamma-linolenic acid (dgla) as the active ingredient
US14/644,231 US9943495B2 (en) 2005-02-14 2015-03-11 Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient
US15/911,806 US10342773B2 (en) 2005-02-14 2018-03-05 Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005036235A JP5546087B2 (en) 2005-02-14 2005-02-14 Oral treatment or prevention agent for skin diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012013311A Division JP2012082226A (en) 2012-01-25 2012-01-25 Oral agent for treatment or prevention of cutaneous disease

Publications (3)

Publication Number Publication Date
JP2006219454A JP2006219454A (en) 2006-08-24
JP2006219454A5 true JP2006219454A5 (en) 2008-03-27
JP5546087B2 JP5546087B2 (en) 2014-07-09

Family

ID=36981996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005036235A Active JP5546087B2 (en) 2005-02-14 2005-02-14 Oral treatment or prevention agent for skin diseases

Country Status (2)

Country Link
JP (1) JP5546087B2 (en)
CN (1) CN101019853B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1852114B1 (en) 2005-02-14 2019-09-18 Suntory Holdings Limited Composition containing dihomo-y-linolenic acid (dgla) as active ingredient
JP2006306812A (en) * 2005-04-28 2006-11-09 Suntory Ltd Acidocyte infiltration inhibitor
JP2006306813A (en) * 2005-04-28 2006-11-09 Suntory Ltd Mast cell increase inhibitor
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
JPWO2012153832A1 (en) 2011-05-12 2014-07-31 日本水産株式会社 Skin composition for inflammatory diseases
US9855236B2 (en) 2011-10-19 2018-01-02 Ds Biopharma Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014119948A (en) * 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед PHARMACEUTICAL COMPOSITIONS CONTAINING DGLA AND / OR 15-HETrE, AND WAYS OF THEIR APPLICATION
ES2875965T3 (en) 2013-12-04 2021-11-11 Nippon Suisan Kaisha Ltd Microbial oil containing dihomo-gamma-linolenic acid and microbial biomass containing dihomo-gamma-linolenic acid
BR112016028518A2 (en) 2014-06-04 2017-08-22 Dignity Sciences Ltd pharmaceutical compositions comprising dgla and use thereof
JP2019501190A (en) * 2016-01-07 2019-01-17 ディーエス バイオファーマ リミテッド Pharmaceutical compositions containing DGLA and uses thereof
PT3463332T (en) * 2016-06-01 2021-06-30 Nestle Sa Composition for use in the prophylaxis of allergic disease
CN110996937A (en) * 2017-05-19 2020-04-10 Ds生物制药有限公司 Pharmaceutical composition comprising DGLA and uses thereof
WO2021065659A1 (en) * 2019-10-01 2021-04-08 サントリーホールディングス株式会社 Composition for improving intestinal function through expression control of aquaporin 3, and use thereof
WO2023063322A1 (en) * 2021-10-13 2023-04-20 花王株式会社 Agent for preventing, treating, or improving inflammatory skin disease
WO2023063321A1 (en) * 2021-10-13 2023-04-20 花王株式会社 Anti-allergic agent
WO2023181755A1 (en) * 2022-03-22 2023-09-28 東洋紡株式会社 Expression regulator for gene involved in skin function-associated factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47777B1 (en) * 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
GB8806737D0 (en) * 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
JP2002047176A (en) * 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd Ige production suppressing agent

Similar Documents

Publication Publication Date Title
JP2006219454A5 (en)
CA2549103C (en) Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US6630157B1 (en) Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides
US10039742B2 (en) Sn-2-monoacylglycerols and lipid malabsorption
JP2007523049A5 (en)
NZ600740A (en) Compositions containing pufa and/or uridine and methods of use thereof
WO2009091538A8 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
SI2443246T1 (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
NO20076382L (en) Use of docosahexa glycerides in the treatment of tumorigenic diseases
JP2021508321A (en) Compositions for use in the treatment and / or amelioration of sleep and mood disorders
JPWO2009038095A1 (en) Composition containing sesamin and vitamin B1
JP2006306812A5 (en)
JP2006306813A5 (en)
RU2771277C2 (en) Treatment of traumatic brain injury
CN117202796A (en) Oral dosage composition for therapeutic production of tributyrin butyrate in the intestinal tract
JP2007326799A5 (en)
JP2005524629A5 (en)
JP2009539968A (en) Composition and kit comprising melatonin component and omega-3-fatty acid component
JP4852296B2 (en) Vasculitis syndrome prevention / treatment agent
JP5759663B2 (en) Skin barrier function improver, etc.
JP2012077022A (en) Composition for inhibiting il-8 expression
US20160263072A1 (en) Monoacylglycerols and fat-soluble nutrients for use in the treatment of malabsorption having a non-mechanical basis
JP2007230912A (en) Nerve regeneration promoter and functional food containing the promoter
JP2006254885A (en) Food and drink for amelioration and prophylaxis of pollinosis